CME Group price target raised to $173 from $169 at Rosenblatt

Rosenblatt analyst Andrew Bond raised the firm’s price target on CME Group to $173 from $169 and keeps a Sell rating on the shares. CME posted a “strong beat” and some “increasingly positive trends remain,” but volumes quarter-to-date have softened and the firm remains Sell rated on the name given a “sector high” EBITDA multiple.